Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Another tough year for Glaxo - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Jun 8, 2000

    Another tough year for Glaxo

    India’s premier pharmaceutical company Glaxo India seems to be undergoing yet another tough year. While the prime reason seems to be the continuing slowdown in the pharmaceutical industry the threat from unbranded generics is eating into the company’s margins.

    Unbranded generics constitute products of pharmaceutical companies who sell their formulations to the trade without their labels at discounted prices. The discounts in case of unbranded generics are almost 50% higher than the normal trade margins .

    Products Wholesale margins Retail Margins
    Under DPCO 8.0% 16.0%
    Out of DPCO 10.0% 20.0%

    Even last year, through Glaxo’s premier anti–ulcer product Zinetac saw a 27.7% growth overall, the company had to drop its prices by 33%. In the current year even the top Indian companies such as Ranbaxy, Cipla, Dr. Reddy’s and Cadila Healthcare have ventured aggressively in the unbranded generic segment which has further aggravated the situation for companies such as Glaxo.

    Overall only 5 products viz. the Betnovate range, Zinetac, Corbadex, Betnesol and Becadexamin capsules showed a decent growth last year and this year the company would have to continue depending on these.

    Products Category Growth in 1999
    Betnovate Range Dermatological 22.0%
    Betnesol Tab. Dermatological 2.0%
    Betnesol Inj. Dermatological -5.0%
    Betnesol nE/E drops Dermatological 18.0%
    Zinetac Tab. Anti–ulcer 22.0%
    Cetzine Tab. Anti–histamine 2.0%
    Corbadex/Vibelan Cap. Mineral supplement 28.0%
    Ceftum Antibiotic 6.0%
    Phexin Antibiotic 1.0%
    Becadexamin Cap. Vitamin 17.0%
    Supacef Antibiotic 8.0%
    Priton Antibiotic -23.0%
    Dilosyn Antibiotic -2.0%
    Betnelan Tab. Antibiotic -10.0%
    Ostocalcium Mineral supplement 9.0%

    At the analysts meet held in February, Mr. Khusrokhan had announced a three pronged strategic direction for the company in the coming years

    • Concentrate on the therapy areas of the future such as respiratory, anti–virals
    • Consolidation in the therapy areas of dermatologicals, antibiotics, gastrointestinals
    • Sell of the tail end brands and continue with the cash cows of cough cold, analgesics, vitamins and systemic steroids.

    There have been unconfirmed reports that Glaxo has reportedly sold one of its tail end brands in the current year. However, it is not known as to which of the brands the company has sold.

    The stock currently quotes at Rs 404 which implies an earning multiples of 34.5 times if one takes into account the expected FY2000 EPS of Rs 11.70. Over the last fortnight the stock has gone up smartly by almost 33% but we believe the outperformance cannot continue for long.



    Equitymaster requests your view! Post a comment on "Another tough year for Glaxo". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 18, 2017 (Close)


    • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks


    Compare Company With Charts